Besides that, it was discovered that tumors with DNA polymerase epsilon (POLE)/POLD1 mutations had higher proportions of CD8+ tumor-infiltrating lymphocytes, indicating that patients with this kind may benefit more from immune checkpoint inhibitor therapy. Here, POLD1 is linked to neoplasm.